Abstract
Background
The objective of the present study was to verify whether chronic renal patients on hemodialysis (HD) with residual diuresis who were using small doses of furosemide present different levels of urinary volume and sodium excretion compared to patients with residual diuresis who do not use this drug.
Methods
We studied 19 chronic renal patients on HD who presented any level of residual diuresis. Urine was collected during the 24-h interdialytic period, and physical examinations and blood sampling took place immediately before the start of HD. Patients were divided into two groups: the diuretic group (DG, n = 10), in which patients had been using 40 mg of furosemide for at least 3 months, and the non-diuretic group (NDG, n = 9), in which patients used no diuretics.
Results
Although both groups presented the same average glomerular filtration rate (p > 0.05) and time in dialysis (p > 0.05) the DG presented an average of twice the urinary volume in 24 h (1142 ± 184 vs. 453 ± 135 ml/24 h, respectively; p = 0.008) and double the total excreted sodium mass compared to patients in the NDG (112 ± 22.4 vs. 45.2 ± 16.0 mEq/24 h, respectively; p = 0.02).
Conclusion
The results of this study have shown that chronic use of small doses of furosemide in chronic renal patients with residual diuresis could increase urinary volume and sodium excretion compared to patients who did not use this drug.
Similar content being viewed by others
References
Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38(1):85–90.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1–266.
Rottembourg J, Issad B, Gallego JL, Degoulet P, Aime F, Gueffaf B, Legrain M. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc. 1983;19:397–403.
Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans. 1991;37(4):598–604.
Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11(3):556–64.
Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(3):1128–33.
Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial. 2004;17(3):196–201.
Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis. 2007;49(3):426–31.
Krediet RT, Douma CE, van Olden RW, Ho-dac-Pannekeet MM, Struijk DG. Augmenting solute clearance in peritoneal dialysis. Kidney Int. 1998;54(6):2218–25.
Boesken WH, Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin Nephrol. 1997;48(1):22–8.
van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol. 1992;12(5):351–6.
Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309(25):1543–6.
Katopodis KP, Chasiotis G, Nikolopoulos P, Seferiadis K, Siamopoulos KC. The influence of 24 h urine sampling on the evaluation of renal dysfunction. Nephrol Dial Transplant. 2007;22(11):3360–2.
Rose B. Pathophysiology of renal disease. New York: McGraw-Hill; 1987.
Caravaca F, Arrobas M, Pizarro JL, Sanchez-Casado E. Uraemic symptoms, nutritional status and renal function in pre-dialysis end-stage renal failure patients. Nephrol Dial Transplant. 2001;16(4):776–82.
van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7(5):745–50.
Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36(4):682–9.
Russo D, Memoli B, Andreucci VE. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol. 1992;38(Suppl 1):S69–73.
Sanjay S, Annigeri RA, Seshadri R, Rao BS, Prakash KC, Mani MK. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton). 2008;13(3):247–50.
Schmidt P, Loew D, Dycka J, Kopsa H, Balcke P, Zazgornik J, Deutsch E. Comparison of the effects of muzolimine and furosemide in patients with end stage renal failure on chronic dialysis. Eur J Clin Pharmacol. 1981;20(1):23–6.
van Olden RW, van Meyel JJ, Gerlag PG. Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol. 1995;47(6):483–8.
Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632–40.
Van Stone J. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J. 1995;41(3):M713–6.
Hakim RM. Clinical implications of biocompatibility in blood purification membranes. Nephrol Dial Transplant. 2000;15(Suppl 2):16–20.
Pertosa G, Grandaliano G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl. 2000;76:S104–11.
Smeby LC, Wideroe TE, Balstad T, Jorstad S. Biocompatibility aspects of cellophane, cellulose acetate, polyacrylonitrile, polysulfone and polycarbonate hemodialyzers. Blood Purif. 1986;4(1–3):93–101.
Brater DC, Anderson SA, Brown-Cartwright D. Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther. 1986;40(2):134–9.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Lemes, H.P., Araujo, S., Nascimento, D. et al. Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin Exp Nephrol 15, 554–559 (2011). https://doi.org/10.1007/s10157-011-0427-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-011-0427-z